Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 17:10:2045125320967197.
doi: 10.1177/2045125320967197. eCollection 2020.

New psychoactive substances: a review and updates

Affiliations
Review

New psychoactive substances: a review and updates

Abu Shafi et al. Ther Adv Psychopharmacol. .

Abstract

New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids and benzodiazepines). We review these four classes of NPS, including their chemical structures, mechanism of action, modes of use, intended intoxicant effects, and their associated physical and mental health harms. The current challenges faced by laboratory testing for NPS are also explored, in the context of the diverse range of NPS currently available, rate of production and emergence of new substances, the different formulations, and methods of acquisition and distribution.

Keywords: NPS; laboratory testing; new psychoactive substances; synthetic cannabinoid receptor agonists; synthetic hallucinogens; synthetic opioids; synthetic stimulants.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Similar articles

Cited by

References

    1. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol 2020; 94: 1085–1133. - PMC - PubMed
    1. Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet 2019; 394: 1668–1684. - PubMed
    1. Soussan C, Kjellgren A. The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. Int J Drug Policy 2016; 32: 77–84. - PubMed
    1. O’Hagan A, McCormack S. To what extent has the United Kingdom law on psychoactive substances been successful? Forensic Res Criminol 2019; 7: 176–183.
    1. Batisse A, Eiden C, Peyriere H, et al. Use of new psychoactive substances to mimic prescription drugs: the trend in France. Neurotoxicology 2020; 79: 20–24. - PubMed

LinkOut - more resources